Fortescue Ltd

FMG

Fortescue Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia. The firm's segments include Metals and Energy. Metals segment includes exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. Its metals business comprises its iron ore operations in the Pilbara as well as a pipeline of exploration projects globally including in Gabon in Africa, Latin America and Australia. The firm's metals business includes Hedland operations, Chichester Hub, Western Hub, Iron Bridge, Green Metal Project, integrated operations, Belinga Project, Blacksmith Project and Pilbara Energy Connect (PEC) project. Energy segment undertakes activities in the global development of green electricity, green hydrogen, green ammonia projects, as well as green technology development and manufacturing. Its energy business includes Arizona Hydrogen project, Holmaneset project, Pecem project and Gladstone PEM50 Project.

Pilbara Minerals Limited

PLS

Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 877 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australia’s resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.

Yancoal Australia Limited

YAL

Yancoal Australia Ltd. engages in the identification, development, and operation of coal related resources. The company is headquartered in Sydney, New South Wales and currently employs 3,900 full-time employees. The company went IPO on 2012-06-28. The Company’s business activity is the production of thermal and metallurgical coal for use in the power generation and steel industries in Asian markets. The company owns and operates several mines and mine sites across Australia. The company owns or operates eight producing coal mines across New South Wales, Queensland and Western Australia. Its mines include Moolarben, Mount Thorley Warkworth, Hunter Valley Operations, Ashton, Yarrabee, Cameby Downs, Middlemount, and Premier Coal. Its thermal coal is primarily used in electricity generation and its end users are typically power and utilities companies. The Moolarben Coal Complex is located approximately 40 kilometers north of Mudgee in Western Coalfields of New South Wales. Mount Thorley Warkworth is an integrated operation consisting of the open cut coal mining operations of Mount Thorley Operations and Warkworth Mine.

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.